ArticleMolecular medicine reports2026
FOSL2 drives transcriptional activation of super‑enhancer-regulated
Article in Molecular medicine reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypoxia is a hallmark of oral squamous cell carcinoma (OSCC) and plays a critical role in driving tumor progression. However, the mechanisms by which OSCC cells respond to hypoxic signaling to promote malignant phenotypes remain unclear. The present study aimed to identify the key regulatory factors governing hypoxic adaptation in OSCC. Based on bulk RNA‑sequencing (RNA‑seq) data from The Cancer Genome Atlas (TCGA) database, hypoxia was identified as a prognostic risk factor for OSCC. Hierarchical clustering revealed 'glycolysis' and 'hypoxia' as the most strongly associated cancer hallmarks. Using single‑cell RNA‑seq data from the Gene Expression Omnibus (GEO) database, 104 hypoxia‑ and glycolysis‑associated genes were identified. Integration of bulk RNA‑seq data from TCGA and GEO databases enabled the development of an optimized prognostic model [stepwise Cox (backward) + elastic network (α=0.8)] through machine learning and highlighted four core genes: Heparan sulfate proteoglycan 2, immunoglobulin superfamily member 3, dihydrouridine synthase 1‑like and dynein cytoplasmic 1 heavy chain 1 (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.